|Bid||2.0900 x 4000|
|Ask||2.2400 x 2200|
|Day's range||2.1341 - 2.3499|
|52-week range||2.0400 - 49.2000|
|Beta (5Y monthly)||2.15|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
To the annoyance of some shareholders, RedHill Biopharma Ltd. ( NASDAQ:RDHL ) shares are down a considerable 41% in the...
Key Insights The considerable ownership by individual investors in RedHill Biopharma indicates that they collectively...
Market forces rained on the parade of RedHill Biopharma Ltd. ( NASDAQ:RDHL ) shareholders today, when the covering...
RedHill Biopharma ( NASDAQ:RDHL ) Second Quarter 2022 Results Key Financial Results Revenue: US$18.3m (down 15% from 2Q...
We feel now is a pretty good time to analyse RedHill Biopharma Ltd.'s ( NASDAQ:RDHL ) business as it appears the...
RedHill Biopharma (RDHL) receives a new patent from the United States Patent and Trademark Office for its investigational COVID-19 candidate, opaganib, in COVID-19 patients with pneumonia. Stock up.
RedHill's (RDHL) RHB-204 gets Orphan Drug designation from the European Commission for the treatment of nontuberculous mycobacteria (NTM) disease
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see...